@article{d95b749f22df41d0a918bcb9302016d1,
title = "Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity",
abstract = "High-fat diet compromises anti-tumor immunity by interfering with metabolism in the tumor microenvironment.",
keywords = "CD8+ T cells, anti-tumor immunity, colorectal cancer, fat oxidation, metabolism, obesity, tumor microenvironment",
author = "Ringel, {Alison E.} and Drijvers, {Jefte M.} and Baker, {Gregory J.} and Alessia Catozzi and Garc{\'i}a-Ca{\~n}averas, {Juan C.} and Gassaway, {Brandon M.} and Miller, {Brian C.} and Juneja, {Vikram R.} and Nguyen, {Thao H.} and Shakchhi Joshi and Yao, {Cong Hui} and Haejin Yoon and Sage, {Peter T.} and LaFleur, {Martin W.} and Trombley, {Justin D.} and Jacobson, {Connor A.} and Zoltan Maliga and Gygi, {Steven P.} and Sorger, {Peter K.} and Rabinowitz, {Joshua D.} and Sharpe, {Arlene H.} and Haigis, {Marcia C.}",
note = "Funding Information: We are grateful for resources provided by the “MicRoN core at Harvard Medical School” and “HMS Immunology Flow Cytometry Core Facility.” This study was supported by grants from the Ludwig Center at Harvard Medical School (United States; to M.C.H., A.H.S., and P.K.S), NCI (National Cancer Institute, United States; U54-CA225088 to M.C.H., A.H.S., and P.K.S. and R01CA213062 to M.C.H.), the Evergrande Center for Immunologic Disease (to A.H.S.), the Glenn Foundation for Medical Research (United States; to M.C.H.), and NIH ( National Institute of Diabetes and Digestive and Kidney Diseases, United States; R01DK103295 to M.C.H. and P01 AI56299 to A.H.S). A.E.R was supported by postdoctoral fellowships from the American Cancer Society (United States; 130373-PF-17-132-01-CCG ) and Cell Biology Education and Fellowship Fund (United States; Harvard Medical School) . J.M.D. was supported by a predoctoral F31 NIH fellowship (National Institutes of Health, United States; 5F31CA224601 ). M.W.L. was supported by a predoctoral T32 NIH fellowship (National Institutes of Health, United States; T32CA207021 ). The VUMC Hormone Assay & Analytical Services and Lipid Cores are supported by NIH (National Institute of Diabetes and Digestive and Kidney Diseases, United States; DK059637 to MMPC and DK020593 to DRTC). Funding Information: We are grateful for resources provided by the ?MicRoN core at Harvard Medical School? and ?HMS Immunology Flow Cytometry Core Facility.? This study was supported by grants from the Ludwig Center at Harvard Medical School (United States; to M.C.H. A.H.S. and P.K.S), NCI (National Cancer Institute, United States; U54-CA225088 to M.C.H. A.H.S. and P.K.S. and R01CA213062 to M.C.H.), the Evergrande Center for Immunologic Disease (to A.H.S.), the Glenn Foundation for Medical Research (United States; to M.C.H.), and NIH (National Institute of Diabetes and Digestive and Kidney Diseases, United States; R01DK103295 to M.C.H. and P01 AI56299 to A.H.S). A.E.R was supported by postdoctoral fellowships from the American Cancer Society (United States; 130373-PF-17-132-01-CCG) and Cell Biology Education and Fellowship Fund (United States; Harvard Medical School). J.M.D. was supported by a predoctoral F31 NIH fellowship (National Institutes of Health, United States; 5F31CA224601). M.W.L. was supported by a predoctoral T32 NIH fellowship (National Institutes of Health, United States; T32CA207021). The VUMC Hormone Assay & Analytical Services and Lipid Cores are supported by NIH (National Institute of Diabetes and Digestive and Kidney Diseases, United States; DK059637 to MMPC and DK020593 to DRTC). Conceptualization, A.E.R. J.M.D. M.C.H. and A.H.S.; Software, G.J.B. A.E.R. and B.C.M.; Formal Analysis, A.E.R. J.M.D. and G.J.B.; Investigation, A.E.R. J.M.D. G.J.B. A.C. J.C.G.-C. B.M.G. B.C.M. V.R.J. T.H.N. S.J. C.-H.Y. H.Y. P.T.S. M.W.L. J.D.T. C.A.J. and Z.M.; Writing ? Original Draft, A.E.R. and J.M.D.; Writing ? Review & Editing, A.E.R. J.M.D. M.C.H. and A.H.S.; Visualization, A.E.R. and J.M.D.; Supervision, M.C.H. A.H.S. S.P.G. P.K.S. and J.D.R.; Funding Acquisition, M.C.H. and A.H.S. A.H.S. has patents/pending royalties on intellectual property on the PD-1 pathway from Roche and Novartis. A.H.S. is on advisory boards for Surface Oncology, Elstar, SQZ Biotechnologies, Selecta, Elpiscience, and Monopteros and has research funding from Novartis, Roche, Ipsen, Quark, and Merck. M.C.H. has patents pending on the PHD3 pathway, is on the scientific advisory board for Pori Therapeutics, and has research funding from Roche. J.M.D. has consulted for ElevateBio and Third Rock Ventures. The remaining authors declare no competing interests. Funding Information: A.H.S. has patents/pending royalties on intellectual property on the PD-1 pathway from Roche and Novartis. A.H.S. is on advisory boards for Surface Oncology, Elstar, SQZ Biotechnologies, Selecta, Elpiscience, and Monopteros and has research funding from Novartis, Roche, Ipsen, Quark, and Merck. M.C.H. has patents pending on the PHD3 pathway, is on the scientific advisory board for Pori Therapeutics, and has research funding from Roche. J.M.D. has consulted for ElevateBio and Third Rock Ventures. The remaining authors declare no competing interests. Publisher Copyright: {\textcopyright} 2020",
year = "2020",
month = dec,
day = "23",
doi = "https://doi.org/10.1016/j.cell.2020.11.009",
language = "American English",
volume = "183",
pages = "1848--1866.e26",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "7",
}